Johnson & Johnson (NYSE: JNJ) has increased its 2023 sales and earnings estimates for a second consecutive quarter.
The US healthcare giant did so after reporting another impressive set of financial results for the latest three-month period.
From April to June, reported sales grew by 6.3% compared to the second quarter of 2022, coming in at $25.53 billion.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze